ArticleSAGE open medical case reports2025
Advanced intestinal-type ampullary cancer successfully treated using combination therapy with gemcitabine, cisplatin, and durvalumab: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 65-year-old Japanese man presented with right-sided abdominal pain. Findings from computed tomography, esophagogastroduodenoscopy, and endoscopic ultrasound-guided tissue acquisition led to a diagnosis of ampullary cancer with para-aortic lymph node metastasis. To treat the biliary obstruction, a metallic stent was placed endoscopically. Combination therapy comprising gemcitabine-, cisplatin-, and durvalumab-induced marked regression of the lymph node metastases, and the patient's carbohydrate antigen 19-9 levels decreased to within normal limits. After eight gemcitabine, cisplatin, and durvalumab therapy cycles, the treatment was switched to maintenance durvalumab monotherapy. This monotherapy was continued for four cycles without adverse effects, and it maintained the metastatic lymph node's regression and the decreased carbohydrate antigen 19-9 levels. No stent occlusion was observed. Histopathological examination of the biopsy specimen obtained before treatment initiation revealed intestinal-type ampullary cancer, and programmed cell death ligand 1 expression was positive in 10% of tumor cells and 5% of immune cells. Despite the limited evidence regarding the long-term efficacy of gemcitabine, cisplatin, and durvalumab therapy in ampullary cancer, this case report demonstrates its sustained effectiveness over 18 months in a patient with intestinal-type ampullary cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.